-transparent.png){kind=logo}
The intravenous administration of high doses of methylprednisolone and cyclophosphamide during pretreatment of the heart-beating canine and human cadaveric allograft donor has caused no observable adverse effect on renal allografts. This is in contrast to that noted when high doses of these drugs are added to the preservation perfusate in which they are not metabolized and may possibly cause renal damage.
Related Publications
H Zincke, and
J E Woods, and
K E Holley
June 1975,
Transplantation,
H Zincke, and
J E Woods, and
K E Holley
January 1976,
Nephron,
H Zincke, and
J E Woods, and
K E Holley
January 1975,
The Journal of surgical research,
H Zincke, and
J E Woods, and
K E Holley
June 1980,
Transplantation proceedings,
H Zincke, and
J E Woods, and
K E Holley
August 2005,
Thrombosis and haemostasis,
H Zincke, and
J E Woods, and
K E Holley
March 1970,
Cancer,
H Zincke, and
J E Woods, and
K E Holley
January 1983,
Terapevticheskii arkhiv,
H Zincke, and
J E Woods, and
K E Holley
February 1976,
Transplantation,
H Zincke, and
J E Woods, and
K E Holley
April 2010,
The British journal of dermatology,
H Zincke, and
J E Woods, and
K E Holley
January 1973,
Arzneimittel-Forschung,
